[HTML][HTML] Harmonization of Molecular Monitoring of CML Therapy in Europe–Perspective of Widespread Competence in BCR-ABL Quantification.
MC Müller, NCP Cross, P Erben, T Schenk, T Ernst… - Blood, 2009 - Elsevier
Abstract Abstract 2616 Poster Board II-592 Introduction: The high efficacy of standard
treatment of chronic myeloid leukemia (CML) with imatinib has prompted the need for …
treatment of chronic myeloid leukemia (CML) with imatinib has prompted the need for …
Harmonization of molecular monitoring of CML therapy in Europe
MC Müller, NCP Cross, P Erben, T Schenk, B Hanfstein… - Leukemia, 2009 - nature.com
The high efficacy of the standard treatment of chronic myeloid leukemia (CML) with imatinib
has prompted the need for accurate methods to monitor response at levels below the …
has prompted the need for accurate methods to monitor response at levels below the …
[HTML][HTML] Equivalence of BCR-ABL Transcript Levels< 1% According to the International Scale with Complete Cytogenetic Response in Chronic Phase CML Patients.
M Lauseker, B Hanfstein, C Haferlach, S Schnittger… - Blood, 2012 - Elsevier
Abstract Abstract 2495 Introduction: Response to therapy in patients with chronic myeloid
leukemia (CML) is monitored by both cytogenetic assessment of bone marrow metaphases …
leukemia (CML) is monitored by both cytogenetic assessment of bone marrow metaphases …
[HTML][HTML] Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study
HE White, M Salmon, F Albano, CSA Andersen… - Leukemia, 2022 - nature.com
Standardized monitoring of BCR:: ABL1 mRNA levels is essential for the management of
chronic myeloid leukemia (CML) patients. From 2016 to 2021 the European Treatment and …
chronic myeloid leukemia (CML) patients. From 2016 to 2021 the European Treatment and …
Stability of conversion factors for BCR-ABL monitoring-–implications for the frequency of validation rounds
MC Müller, U Munjal, P Erben, T Lion… - 2010 - ashpublications.org
Abstract Abstract 893 Introduction: A European collaborative harmonization study involving
61 laboratories is being conducted under the auspices of the European Treatment and …
61 laboratories is being conducted under the auspices of the European Treatment and …
Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and …
H Kantarjian, C Schiffer, D Jones… - Blood, The Journal of …, 2008 - ashpublications.org
The management of hematologic malignancies, including chronic myeloid leukemia (CML),
chronic lymphocytic leukemia (CLL), and acute lymphocytic leukemia (ALL), has led the way …
chronic lymphocytic leukemia (CLL), and acute lymphocytic leukemia (ALL), has led the way …
International reporting scale of BCR-ABL1 fusion transcript in chronic myeloid leukemia: First report from India
P Balasubramanian, E Chendamarai, P Markose… - Acta …, 2012 - karger.com
Achieving a major molecular response (MMR) is an important predictor of progression-free
survival in chronic myeloid leukemia patients treated with imatinib. This requires accurate …
survival in chronic myeloid leukemia patients treated with imatinib. This requires accurate …
[HTML][HTML] Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission
M Serpa, SS Sanabani, PE Dorliac-Llacer, M Conchon… - BMC Hematology, 2010 - Springer
Background The monitoring of BCR-ABL transcript levels by real-time quantitative
polymerase chain reaction (RT-qPCR) has become important to assess minimal residual …
polymerase chain reaction (RT-qPCR) has become important to assess minimal residual …
Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia
Molecular monitoring for patients with chronic myeloid leukaemia (CML) has become an
important practice in the era of imatinib therapy. For successful widespread introduction into …
important practice in the era of imatinib therapy. For successful widespread introduction into …
Comparison of molecular responses based on BCR-ABL1%IS results from an in-house TaqMan-based qPCR versus Xpert® assay in CML patients on tyrosine …
N Boeckx, CV Laer, JD Roover, B Wilmsen… - Acta Clinica …, 2015 - Taylor & Francis
Abstract Objectives: Tyrosine kinase inhibitors (TKIs) have drastically changed the prospects
for chronic myeloid leukemia (CML) patients. The European LeukemiaNet (ELN) …
for chronic myeloid leukemia (CML) patients. The European LeukemiaNet (ELN) …